Live Breaking News & Updates on Cancer Genome Computational Analysis Group

With biotech funding at ‘all-time high,’ Scorpion scoops up $162 million
By Anissa Gardizy Globe Staff,Updated January 7, 2021, 7:00 a.m.
Email to a Friend
Just over two months after announcing its debut with $108 million in funding, Boston startup
Scorpion Therapeutics said Thursday it has raised an even larger amount of venture capital.
Scorpion, which focuses on “precision medicine” for cancer, said it has completed a $162 million funding round, bringing the biotech’s total venture haul to about $270 million. It’s a large amount for a new company that so far has kept much of its work under wraps, and a sign that the region’s early-stage biotech industry is vibrant, despite the pandemic. ....

New York , United States , New Zealand General , New Zealand , San Francisco , Gaddy Getz , Keith Flaherty , Eli Lilly , Broad Institute , Wellington Management Company , Cancer Center At Massachusetts , Boxer Capital Of Tavistock Group , Harvard Medical School , Cancer Genome Computational Analysis Group , Atlas Venture , Bristol Myers Squibb , Seaport District , Boxer Capital , Tavistock Group , Omega Funds , Vida Ventures , Surveyor Capital Management , Invus Public Equities , Loxo Oncology , Liron Bar Peled , Cancer Center ,